Crescita Therapeutics Full Year 2022 Earnings: EPS: CA$0.042 (vs CA$0.053 loss in FY 2021)
Crescita Therapeutics (TSE:CTX) Full Year 2022 Results
Key Financial Results
- Revenue: CA$23.5m (up 40% from FY 2021).
- Net income: CA$862.0k (up from CA$1.11m loss in FY 2021).
- Profit margin: 3.7% (up from net loss in FY 2021).
- EPS: CA$0.042 (up from CA$0.053 loss in FY 2021).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Crescita Therapeutics shares are up 1.4% from a week ago.
You still need to take note of risks, for example - Crescita Therapeutics has 2 warning signs we think you should be aware of.
Valuation is complex, but we're helping make it simple.
Find out whether Crescita Therapeutics is potentially over or undervalued by checking out our comprehensive analysis, which includes fair value estimates, risks and warnings, dividends, insider transactions and financial health.View the Free Analysis
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Crescita Therapeutics Inc., a dermatology company, provides non-prescription skincare products and prescription drug products in Canada, the United States, and internationally.
Flawless balance sheet with questionable track record.